Lupin: Under pressure - Hold
The stock’s valuation is now attractive, but uncertainty in the US market is a concern
The Indian pharmaceutical industry has been going through a tough phase over the last couple of years. While the Nifty 50 index has gained over 15 per cent in absolute terms over the last two years, the Nifty pharma index has fallen nearly 33 per cent.Major pain points such as regulatory issues in the US market and pressure on drug pricing in the key markets have continued to weigh on the revenue ...
Please Wait while comments are loading...
This article is closed for comments.
Please Email the Editor
Comments to:
Copyright ©2017, The Hindu Business Line